{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:23Z","timestamp":1790767343452,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2021,9,6]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Diazoxide (DZX) is the drug of choice for treating hyperinsulinaemic hypoglycaemia (HH), and it has potentially serious adverse effects. We studied the safety and efficacy of low-dose DZX in small-for-gestational-age (SGA) infants with HH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>An observational cohort study from 1 September 2014 to 31 September 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>A tertiary Women\u2019s and Children\u2019s Hospital in Singapore.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>All SGA infants with HH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Diazoxide, at 3\u20135\u2009mg\/kg\/day.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Short-term outcomes; adverse drug events and fasting studies to determine \u2018safe to go home\u2019 and \u2018resolution\u2019 of HH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 71\u2009836 live births, 11\u2009493 (16%) were SGA. Fifty-six (0.5%) SGA infants with HH were identified, of which 27 (47%) with a mean gestational age of 36.4\u00b12 weeks and birth weight of 1942\u00b1356\u2009g required DZX treatment. Diazoxide was initiated at 3\u2009mg\/kg\/day at a median age of 10 days. The mean effective dose was 4.6\u00b12.2\u2009mg\/kg\/day, with 24\/27 (89%) receiving 3\u20135\u2009mg\/kg\/day. Generalised hypertrichosis occurred in 2 (7.4%) and fluid retention in 1 (3.7%) infant. A fasting study was performed before home while on DZX in 26\/27 (96%) cases. Diazoxide was discontinued at a median age of 63 days (9\u2013198\u2009days), and resolution of HH was confirmed in 26\/27 (96%) infants on passing a fasting study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study demonstrates that low-dose DZX effectively treats SGA infants with HH as measured by fasting studies. Although the safety profile was excellent, minimal adverse events were still observed with DZX, even at low doses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/archdischild-2021-322845","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T13:36:43Z","timestamp":1632145003000},"page":"359-363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia"],"prefix":"10.1136","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-7441","authenticated-orcid":false,"given":"Suresh","family":"Chandran","sequence":"first","affiliation":[{"name":"Department of Neonatology, KK Women's and Children's Hospital, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin R","family":"R","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KK Women's and Children's Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-751X","authenticated-orcid":false,"given":"Chua","family":"Mei Chien","sequence":"additional","affiliation":[{"name":"Department of Neonatology, KK Women's and Children's Hospital, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ehsan","family":"Saffari","sequence":"additional","affiliation":[{"name":"Center for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Samuel","family":"Rajadurai","sequence":"additional","affiliation":[{"name":"Department of Neonatology, KK Women's and Children's Hospital, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Yap","sequence":"additional","affiliation":[{"name":"Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore"},{"name":"Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"},{"name":"Department of Pediatrics, KK Women's and Children's Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"2025090513530414000_107.4.359.1","doi-asserted-by":"publisher","DOI":"10.1159\/000492859"},{"key":"2025090513530414000_107.4.359.2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s13312-015-0772-1","article-title":"Hyperinsulinemic hypoglycemia in infancy: current concepts in diagnosis and management","volume":"52","author":"Vora","year":"2015","journal-title":"Indian Pediatr"},{"key":"2025090513530414000_107.4.359.3","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.10.1118"},{"key":"2025090513530414000_107.4.359.4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41372-020-00891-w","article-title":"Prolonged transitional neonatal hypoglycaemia: characterisation of a clinical syndrome","volume":"41","author":"Bailey","year":"2021","journal-title":"J Perinatol"},{"key":"2025090513530414000_107.4.359.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.10.002"},{"key":"2025090513530414000_107.4.359.6","unstructured":"National Library of Medicine . DaileyMed. Package insert: Proglycem-diazoxide suspension, 2015. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.2fd9-49af-b923-1dc0d91fd6e2 [Accessed 27 Jun 2021]."},{"key":"2025090513530414000_107.4.359.7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40272-019-00334-w","article-title":"Current and emerging agents for the treatment of hypoglycemia in patients with congenital hyperinsulinism","volume":"21","author":"De Cosio","year":"2019","journal-title":"Paediatr Drugs"},{"key":"2025090513530414000_107.4.359.8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-13-59"},{"key":"2025090513530414000_107.4.359.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80588-1"},{"key":"2025090513530414000_107.4.359.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.03.057"},{"key":"2025090513530414000_107.4.359.11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/jcn.JCN_37_19","article-title":"Physiological and phased approach to newborns at-risk of hyperinsulinemic hypoglycemia: a neonatal perspective","volume":"8","author":"Chandran","year":"2019","journal-title":"J Clin Neonatol"},{"key":"2025090513530414000_107.4.359.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164577","article-title":"Stability of diazoxide in extemporaneously compounded oral suspensions","volume":"11","author":"Friciu","year":"2016","journal-title":"PLoS One"},{"key":"2025090513530414000_107.4.359.13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000454667","article-title":"Medications that increase osmolality and compromise the safety of enteral feeding in preterm infants","volume":"111","author":"Chandran","year":"2017","journal-title":"Neonatology"},{"key":"2025090513530414000_107.4.359.14","article-title":"Evidence-based practices reduce necrotizing enterocolitis and improve nutrition outcomes in very low-birth-weight infants","author":"Chandran","year":"2020","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2025090513530414000_107.4.359.15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1297\/cpe.26.127","article-title":"Clinical practice guidelines for congenital hyperinsulinism","volume":"26","author":"Yorifuji","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"key":"2025090513530414000_107.4.359.16","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.2337\/dc07-s206","article-title":"Increasing prevalence of gestational diabetes mellitus: a public health perspective","volume":"30 Suppl 2","author":"Ferrara","year":"2007","journal-title":"Diabetes Care"},{"key":"2025090513530414000_107.4.359.17","first-page":"1719","article-title":"Analysis of perinatal risk factors for small-for-gestational-age and appropriate-for-gestational-age late-term infants","volume":"19","author":"Cheng","year":"2020","journal-title":"Exp Ther Med"},{"key":"2025090513530414000_107.4.359.18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit","volume":"38","author":"Gray","year":"2018","journal-title":"J Perinatol"},{"key":"2025090513530414000_107.4.359.19","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2012-302880"},{"key":"2025090513530414000_107.4.359.20","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200105000-00002"},{"key":"2025090513530414000_107.4.359.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.17.10188"},{"key":"2025090513530414000_107.4.359.22","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1210\/clinem\/dgaa543","article-title":"Management and appropriate use of diazoxide in infants and children with hyperinsulinism","volume":"105","author":"Brar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090513530414000_107.4.359.23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00431-005-1654-7","article-title":"Ketotic hypoglycaemia in children with diazoxide responsive hyperinsulinism of infancy","volume":"164","author":"Hussain","year":"2005","journal-title":"Eur J Pediatr"},{"key":"2025090513530414000_107.4.359.24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1515\/jpem-2019-0066","article-title":"Characterization of the duration of treatment with diazoxide in infants with prolonged hyperinsulinism (PHI)","volume":"32","author":"Raisingani","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2025090513530414000_107.4.359.25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000478696","article-title":"Population pharmacokinetics of diazoxide in children with hyperinsulinemic hypoglycemia","volume":"88","author":"Kizu","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"2025090513530414000_107.4.359.26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030135"},{"key":"2025090513530414000_107.4.359.27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3202"},{"key":"2025090513530414000_107.4.359.28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1297\/cpe.27.131","article-title":"Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey)","volume":"27","author":"Fukutomi","year":"2018","journal-title":"Clin Pediatr Endocrinol"},{"key":"2025090513530414000_107.4.359.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0367-x","article-title":"Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers","volume":"10","author":"Welters","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2025090513530414000_107.4.359.30","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/jc.2018-01613","article-title":"Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide","volume":"103","author":"Herrera","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090513530414000_107.4.359.31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000507624","article-title":"Pericardial effusion associated with diazoxide treatment for congenital hyperinsulinism","volume":"93","author":"Hastings","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"2025090513530414000_107.4.359.32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"2025090513530414000_107.4.359.33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0039-3400975","article-title":"Cerebral insufficiency caused by diazoxide in a premature neonate with congenital hyperinsulinism","volume":"51","author":"Okada","year":"2020","journal-title":"Neuropediatrics"},{"key":"2025090513530414000_107.4.359.34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.47102\/annals-acadmedsg.V43N6p296","article-title":"Creation and validation of the Singapore birth nomograms for birth weight, length and head circumference based on a 12-year birth cohort","volume":"43","author":"Poon","year":"2014","journal-title":"Ann Acad Med Singap"},{"key":"2025090513530414000_107.4.359.35","doi-asserted-by":"crossref","unstructured":"Feng ZP , Sun HS , Channels ATP-SP . (KATP) play a role in hypoxic preconditioning against neonatal hypoxic\u2013ischemic brain injury. In: Lapchak P , Zhang J , eds. Neuroprotective therapy for stroke and ischemic disease. Springer series in translational stroke research. Springer, Cham, 2017: 185\u2013201.","DOI":"10.1007\/978-3-319-45345-3_7"},{"key":"2025090513530414000_107.4.359.36","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2020-319057"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2021-322845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T20:53:16Z","timestamp":1757105596000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2021-322845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,6,17]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/archdischild-2021-322845"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2021-322845","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]}}}